ClinicalTrials.gg
RecruitingNCT06175494Updated Apr 23, 2024

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

A Phase 3 interventional study of Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) and Recombinant COVID-19 Variant Vaccine (Sf9 Cell) in COVID-19, sponsored by WestVac Biopharma Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by WestVac Biopharma Co., Ltd. · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in COVID-19 by WestVac Biopharma Co., Ltd. — 3 open to participants now, 3 under way, 2 of them phase 3. COVID-19 · WestVac Biopharma Co., Ltd..

Planned enrollment
3rd of 11
4,800 · median 450
Started
2023
with 3 others
Phase 3
3 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in COVID-19 by WestVac Biopharma Co., Ltd., this one is the 3rd largest by planned enrollment, is one of 4 that started in 2023, is one of 3 in phase 3, and was the 10th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 11 studies in COVID-19 by WestVac Biopharma Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in COVID-19 by WestVac Biopharma Co., Ltd., or all of them as a file.
02

Study summary

The Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd. is a monovalent modified vaccine designed against Omicron XBB.1.5.

This is a multi-center, randomized, double-blind, placebo-controlled phase 3 clinical study with two cohorts, i.e. the immuno-bridging observational cohort and the efficacy observational cohort, aims to evaluate the efficacy, safety, and immunogenicity of booster vaccination with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) for the prevention of SARS-CoV-2 infection in a population of 18 years of age and older.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 18 years and above, including those with underlying diseases or .
  2. Basic or booster vaccination with COVID-19 vaccine ≥3 months.
  3. No history of SARS-CoV-2 infection history within 3 months, or never infected.
  4. Have the ability to understand research procedures, with , voluntarily sign informed consent form, and be able to comply with the requirements of clinical study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Axillary temperature ≥37.3℃.
  2. SARS-CoV-2 antigen or nucleic acid screening positive during the screening period.
  3. Anti-SARS-CoV-2 IgM antibody screening positive during the screening period.
  4. It is in the advanced stage of malignant tumor and the disease control is unstable.
  5. Female pregnancy (pregnancy test results are positive), lactation period.
  6. Suffering from serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, heart failure etc.; suffering from severe hypertension that can not be controlled by drugs.
  7. Suffering from other serious chronic conditions such as uncontrolled asthma, diabetes, , pulmonary embolism, chronic kidney disease requiring dialysis, cirrhosis of the liver, convulsions, epilepsy and other neurological/psychiatric conditions.
  8. Have been diagnosed with congenital or acquired immunodeficiency, infection (including anti-HIV antibody positive during the screening period).
  9. People who are allergic to any component of the vaccine and have a history of severe allergies or vaccine allergic reactions in the past.
  10. Congenital or acquired angioedema/neuropathic edema.
  11. Asplenia or functional asplenia.
  12. Thrombocytopenia or other clotting disorders (which may cause intramuscular injection ).
  13. Received another investigational drug within 1 month prior to receiving the investigational vaccine.
  14. Received subunit or inactivated vaccine within 14 days prior to receiving the investigational vaccine, or received within 1 month.
  15. Fertile female subjects did not use effective within 1 month prior to enrollment.
  16. Fertile female and male subjects have pregnancy plans and sperm/egg donation plans from the screening period to 3 months after vaccination.
  17. Medical, psychological, social, or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's signing of .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,800 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

    Biological: Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

  • Active comparator
    Control group

    Recombinant COVID-19 Variant Vaccine( Sf9 Cell)

    Biological: Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

  • Placebo comparator
    Placebo control group

    Placebo control

    Biological: Placebo

Interventions

  • BiologicalRecombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

    boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

  • BiologicalRecombinant COVID-19 Variant Vaccine (Sf9 Cell)

    boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

  • BiologicalPlacebo

    boost with saline

06

What researchers measure

Primary outcomes

  1. Efficacy against COVID-19

    Efficacy against the first occurrence of etiologically confirmed (antigen or PCR-positive) cases of symptomatic COVID-19, regardless of severity, 14 days to 6 months after booster vaccination.

    Time frame: 14 days to 6 months after vaccination

  2. AEs and ARs

    Incidence of adverse events (AEs) and adverse reactions (ARs) 0-7 days after booster vaccination.

    Time frame: 0-7 days after vaccination

Secondary outcomes

  1. Efficacy against COVID-19

    Efficacy against the first occurrence of etiologically confirmed (antigen or PCR-positive) cases of moderate/severe COVID-19 caused by SARS-CoV-2 infection, cases of hospitalization due to COVID-19, and cases of death due to COVID-19, \> 14 days to 6 months after booster vaccination.

    Time frame: 14 days to 6 months after booster vaccination

  2. Efficacy against COVID-19

    Efficacy against the first occurrence of etiologically confirmed (antigen or PCR-positive) cases of symptomatic COVID-19, regardless of severity, 7 days to 6 months after booster vaccination.

    Time frame: 7 days to 6 months after booster vaccination

  3. Efficacy against COVID-19

    Efficacy against the first occurrence of etiologically confirmed (antigen or PCR-positive) cases of moderate/severe COVID-19 caused by SARS-CoV-2 infection, cases of hospitalization due to COVID-19, and cases of death due to COVID-19, \> 7 days to 6 months after booster vaccination.

    Time frame: 7 days to 6 months after booster vaccination

  4. AEs and ARs

    Incidence of adverse events (AEs) and adverse reactions (ARs) 0-30 days after booster vaccination.

    Time frame: 0-30 days after booster vaccination

  5. SAEs and AESIs

    Incidence of serious adverse events (SAE) and adverse events of special interest (AESI) within 12 months after booster vaccination.

    Time frame: within 12 months after booster vaccination

  6. Immunogenicity

    The geometric mean titer (GMT), seroconversion rate and geometric mean fold increase (GMI) of neutralizing antibodies (true virus and pseudo-virus assay) against SARS-CoV-2 Omicron XBB.1.5 variant and the main circulating strain at that time on day 14 after booster vaccination.

    Time frame: day 14 after booster vaccination

  7. Immunogenicity

    The geometric mean titer (GMT), seroconversion rate and geometric mean fold increase (GMI) of neutralizing antibodies (pseudo-virus assay) against SARS-CoV-2 Omicron XBB.1.5 variant and the main circulating strain at that time on day 14, day 30, 3 months and 6 months after booster vaccination.

    Time frame: day 14, day 30, 3 months and 6 months after booster vaccination

  8. Immunogenicity

    The geometric mean titer (GMT), seroconversion rate and geometric mean fold increase (GMI) of IgG antibodies against SARS-CoV-2 S-RBD protein on day 14, day 30, 3 months and 6 months after booster vaccination.

    Time frame: day 14, day 30, 3 months and 6 months after booster vaccination

07

Study locations

1 of 1 sites recruiting
  • Jiangsu Provincial Center for Disease Control and Prevention
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Fengcai Zhu, Medical · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jul 2024, 7 months after the start.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 7 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Dec 19, 2023
StartActual
Dec 19, 2023
Primary completionEst.
Jul 31, 2024
CompletionEst.
Jan 31, 2025
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06175494
Lead sponsor
WestVac Biopharma Co., Ltd.
Collaborators
WestVac Biopharma (Guangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Dec 19, 2023
Start date
Dec 19, 2023
Primary completion
Jul 31, 2024 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Apr 23, 2024

Study contacts

Fengcai Zhu, Medical
Contact
jszfc@jscdc.cn
+86 139 5199 4867
Fengcai Zhu, Medical
principal investigator · Jiangsu Provincial Center for Disease Control and Prevention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion